Selling, General, and Administrative Costs: Viatris Inc. vs Alpine Immune Sciences, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving pharmaceutical and biotechnology sectors, understanding financial health is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Alpine Immune Sciences, Inc. from 2014 to 2023. Viatris, a global healthcare giant, consistently reported SG&A expenses in the billions, peaking at approximately $4.65 billion in 2023. In contrast, Alpine Immune Sciences, a smaller biotech firm, saw its SG&A expenses grow nearly tenfold, from around $2.3 million in 2014 to $22.2 million in 2023. This stark difference highlights the scale and operational scope of these companies. While Viatris's expenses reflect its expansive global operations, Alpine's growth trajectory underscores its increasing investment in research and development. This financial snapshot offers a window into the strategic priorities and market positioning of these two distinct players in the healthcare industry.